Showing results (211-220 of 251) with videos related to

Sort By:
Pageof 26
Aging|April 27, 2022
Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic propertiesJames A McCubrey, Akshaya K Meher, Shaw M Akula, et al.
Cell Cycle (Georgetown, Tex.)|August 27, 2011
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cellsLinda S Steelman, Patrick Navolanic, William H Chappell, et al.
Nature Materials|April 26, 2011
Bioinspired molecular co-catalysts bonded to a silicon photocathode for solar hydrogen evolutionYidong Hou, Billie L Abrams, Peter C K Vesborg, et al.
Cells|March 10, 2022
Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53Stephen L Abrams, Przemysław Duda, Shaw M Akula, et al.
Leukemia|March 26, 2011
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathwayA M Martelli, C Evangelisti, W Chappell, et al.
Leukemia|June 20, 2013
Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic interventionJ A McCubrey, L S Steelman, F E Bertrand, et al.
Advances in Biological Regulation|June 5, 2018
Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell linesWilliam H Chappell, Saverio Candido, Stephen L Abrams, et al.
Expert Opinion on Emerging Drugs|September 1, 2009
Emerging Raf inhibitorsJames A McCubrey, Linda S Steelman, Steven L Abrams, et al.
Expert Opinion on Emerging Drugs|February 16, 2010
Emerging MEK inhibitorsJames A McCubrey, Linda S Steelman, Steven L Abrams, et al.
Advances in Biological Regulation|October 10, 2017
Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells-Power of nutraceuticalsJames A McCubrey, Stephen L Abrams, Kvin Lertpiriyapong, et al.
Pageof 26